Hypera SA, a leading pharmaceutical company based in Brazil, operates on a robust business model. The core of their business involves the manufacturing, marketing, and distribution of a wide range of pharmaceutical products. Hypera SA specializes in both prescription and over-the-counter medications, catering to various therapeutic areas. They also produce medical-hospital products and non-pharmaceutical items such as personal hygiene and beauty care products. With a focus on innovation and quality, Hypera SA aims to improve the health and well-being of individuals across the country. As a prominent player in the pharmaceutical industry, Hypera SA continues to expand its product portfolio, enhance operational efficiency, and ensure customer satisfaction.

Hypera SA is primarily active in the pharmaceutical industry.

The main competitors of Hypera SA in the market are pharmaceutical companies such as Aché Laboratórios, EMS Pharma, and Eurofarma.

Hypera SA, formerly known as Hypermarcas SA, is a leading pharmaceutical company based in Brazil. Founded in 2001, Hypera has a rich history and has significantly grown over the years. It focuses on the development, production, and commercialization of pharmaceutical products, generic drugs, over-the-counter medications, and personal care items. Hypera has established a strong presence in the Brazilian market, offering a wide range of high-quality and affordable healthcare solutions. Its commitment to research and innovation has led to numerous successful product launches. Hypera SA continues to be a prominent player in the pharmaceutical industry, continuously expanding its portfolio and enhancing the well-being of consumers.

Hypera SA, a renowned company in the pharmaceutical industry, has accomplished several significant milestones throughout its journey. The company has successfully positioned itself as a leader in the Latin American market, expanding its presence across various countries. Hypera SA has consistently demonstrated its commitment to innovation and research, introducing numerous breakthrough pharmaceutical products. With strategic acquisitions and partnerships, the company has further strengthened its portfolio and market share. Hypera SA's relentless focus on quality control and strict adherence to regulatory standards has earned it a stellar reputation among industry experts and stakeholders. These achievements reflect Hypera SA's dedication to advancing healthcare solutions and driving long-term growth in the pharmaceutical sector.

Hypera SA is primarily present in Brazil.

Hypera SA represents a strong commitment to its corporate philosophy, which revolves around innovation, excellence, and integrity. With a focus on enhancing quality of life, Hypera SA aims to deliver innovative healthcare solutions to consumers. The company puts a strong emphasis on research and development, constantly striving to introduce new and effective products to market. By promoting a culture of excellence, Hypera SA seeks to provide top-notch customer service and quality-assured products. With a dedication to integrity, the company operates transparently and ethically, ensuring trust and reliability among its stakeholders. Hypera SA's values and corporate philosophy ultimately drive its mission to positively impact people's health and well-being.

Analysts currently set an average price target of 30.54 BRL for the Hypera stock (median: 30.09 BRL), implying +45.9 % versus the latest price. The consensus is based on 19 analyst ratings.

Hypera Analyst Price Targets 2026

19 analysts currently rate the Hypera stock: 13 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Hypera to generate revenue of 9.62 B BRL and earnings per share of 3.00 BRL.

Hypera Analyst Price Targets 2026

Converted at the current exchange rate, the Hypera share trades at 3.61 EUR (21.11 BRL).

The Brazilian company Hypera SA is a leading manufacturer and distributor of pharmaceuticals, dietary supplements, cosmetics, and household products. It has been listed on the stock exchange since 2008 and has built a strong presence in the Brazilian market in recent years. Hypera SA operates in four business segments: Consumer Health, Pharma, Over-the-Counter medicines, and Cosmetics and Skincare products. The Consumer Health division offers a wide range of products such as vitamins, pain relievers, cough and cold medicines, as well as dietary supplements and baby food. Hypera SA's Pharma business includes prescription drugs, including medications for cardiovascular, diabetes, gastroenterology, and oncology patients. Additionally, the company also provides vaccines and medications for respiratory diseases. In the Over-the-Counter medicines segment, the company offers a wide range of non-prescription medications for colds, digestive issues, pain, and allergies. This includes diet and weight loss products, vitamins and minerals, as well as other supplements. Hypera SA also offers a variety of cosmetic and skincare products, including brands like Episol, Hair Fly, Monange, Neostrata, and Assolan. The company also operates a household products division, which includes brands like Vitasay, Tixan, and Blergh. The product range of Hypera SA is diverse, ranging from affordable mass-market products to more expensive premium brands. The company aims to reach a wide range of customers and has specialized in marketing products for the health and beauty segment. It has established relationships with major retail chains as well as pharmacies and other sales locations. Hypera SA strives to integrate innovation and technology into its business model. The company has a research and development team constantly developing and launching new products. It also invests in automation and digitization of its production facilities to improve the efficiency and quality of its products. Overall, Hypera SA's business model is focused on a wide product range and a strong brand presence. The company relies on price competition and innovation to strengthen its market position. As a leading provider of healthcare, cosmetic, and household products in Brazil, the company aims to expand internationally.

The expected revenue of Hypera is 9.62 B BRL. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Hypera is 1.91 B BRL. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Hypera is currently 7.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hypera stock.

The price-to-sales ratio (P/S) of Hypera is currently 1.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hypera stock.

The Eulerpool Quality Score for Hypera is 5/10.

The ISIN of Hypera is BRHYPEACNOR0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Hypera is HYPE3.SA. The ticker symbol is used to trade Hypera shares on the stock exchange.

Over the past 12 months, Hypera paid a dividend of 1.17 BRL . This corresponds to a dividend yield of about 5.53 %. For the coming 12 months, Hypera is expected to pay a dividend of 4.13 BRL.

The current dividend yield of Hypera is 5.53 %.

Hypera pays a dividend, distributed in the months of , , , .

Hypera paid dividends every year for the past 10 years.

For the upcoming 12 months, dividends amounting to 4.13 BRL are expected. This corresponds to a dividend yield of 19.59 %.

Hypera is assigned to the 'Health' sector.

In the year 2025, Hypera distributed 1.17 BRL as dividends.

The dividends of Hypera are distributed in BRL.